Investing.com - BioLineRx reported on Thursday third quarter earnings that missed analysts' forecasts and revenue that was inline with expectations.
BioLineRx announced earnings per share of $-0.1493 on revenue of $0.00. Analysts polled by Investing.com anticipated EPS of $-0.125 on revenue of $0.00.
BioLineRx shares are up 8.69% from the beginning of the year, still down 56.80% from its 52 week high of $6.34 set on May 4. They are under-performing the Nasdaq which is up 23.91% from the start of the year.
BioLineRx shares lost 1.12% in intra-day trade following the report.
BioLineRx follows other major Healthcare sector earnings this month
BioLineRx's report follows an earnings beat by Pfizer on November 2, who reported EPS of $1.34 on revenue of $24.09B, compared to forecasts EPS of $1.08 on revenue of $22.58B.
Novo Nordisk ADR had beat expectations on November 3 with third quarter EPS of $0.8209 on revenue of $5.55B, compared to forecast for EPS of $0.7768 on revenue of $5.39B.
Stay up-to-date on all of the upcoming earnings reports by visiting Investing.com's earnings calendar